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Platinum-based anticancer drugs enhance the immunostimulatory potential of DCs and decrease the
immunosuppressive capacity of tumor cells. This immunomodulatory ability is based on the inhibition of STAT6-
mediated expression of co-inhibitory molecule PD-L2 and opens up the possibility of using these drugs in combination
with other immunostimulatory compounds.
Platinum-based chemotherapeutics are one
of the cornerstones of contemporary cancer
treatment, showing clinical efficacy against
many types of cancers. Their function is
based on the ability to covalently bind
DNA, forming platinum-DNA adducts.
Platinum-DNA adduct formation activates
DNA damage recognition and repair path-
ways and ultimately leads to apoptosis,
explaining thepowerfulcytotoxicproperties.
Until recently these and other anti-
cancer drugs were believed to have an
immunosuppressive effect due to their
myelosuppressive nature. However, recent
findings point to the intriguing possibility
that the opposite may be true. At least
part of the clinical effect of platinum anti-
cancer drugs may be attributed to modu-
lation of the immune system by induction
of immunogenic cell death or sensitization
of tumor cells for T cell killing.
1-3
Previous studies mainly focused on the
effect of platinum drugs on tumor cells,
but the tumor microenvironment also
encompasses immune cells such as dend-
ritic cells (DCs). The effect of platinum
drugs on immune cells has not been
studied in detail. In a recent study we
investigated the effect of platinum drugs
on DC functionality.
4
We exposed monocyte-derived DCs to
clinically relevant concentrations of differ-
ent chemotherapeutic drugs during their
maturation and subsequently assessed their
T cell stimulatory capacity using both
allogeneic and antigen-specific in vitro
assays. We found that only the platinum-
based chemotherapeutics augmented the
capacity of DCs to induce antigen-specific
T cell proliferation. Furthermore, these
T cells displayed increased production
of IFNc and IL-2 upon stimulation.
The increased T cell stimulatory capacity
was not caused by increased expression
of co-stimulatory molecules or increased
secretion of pro-inflammatory cytokines,
but by downregulation of inhibitory
molecules Programmed Death Ligand
(PD-L) 1 and particularly PD-L2 on the
DCs.
PD-L1 and 2 are ligands of PD-1 on T
cells and induce tolerance and anergy.
5
PD-L2 expression is regulated by the IL-4/
Signal transducer and activator of tran-
scription 6 (STAT6) signaling pathway.
Others have shown that IL-4 and IL-13
are abundantly present in the tumor
microenvironment resulting in STAT6
activation.
6 We found that platinum
chemotherapeutics reversed the IL-4
induced phosphorylation of STAT6 in
DCs as detected by westernblot. In
accordance, siRNA mediated knockdown
of STAT6 in DCs decreased the platinum-
induced downregulation of PD-L2 and
abolished the ability of platinum drugs
to enhance T cell proliferation, showing
that this effect is caused by inhibition
of STAT6. These results show that
platinum drugs can modulate immune
responses by relieving inhibitory mechan-
isms (Fig.1) and represent a novel
immune-modulating function of platinum
chemotherapeutics.
Not only antigen-presenting but also
tumor cells express PD-L1 and 2. This
results in evasion of T cell-mediated killing
and is correlated with a poor prognosis.
7
Thus, we hypothesized that platinum
chemotherapeutics could downregulate
PD-L2 on tumor cells. Indeed, also in
tumor cell lines we found that treatment
with platinum drugs resulted in depho-
sphorylation of STAT6 and subsequent
downregulation of PD-L2 (but not PD-
L1) and enhanced recognition by tumor-
specific cytotoxic T cell clones (Fig.1).
To determine the possible clinical
importance of these in vitro findings we
performed a retrospective clinical study.
*Correspondence to: I. Jolanda M. de Vries; Email: J.devries@ncmls.ru.nl
Submitted: 09/15/11; Accepted: 09/16/11
http://dx.doi.org/10.4161/onci.1.2.18126
OncoImmunology 1:2, 234–236; March/April 2012; G 2012 Landes Bioscience
234 OncoImmunology Volume 1 Issue 2© 2012 Landes Bioscience.
Do not distribute.
In this study, we assessed the recurrence-
free survival of patients with squamous cell
head and neck cancer, who had been
treated with either cisplatin in combina-
tion with radiotherapy or radiotherapy
alone and correlated it with the expression
of STAT6 by the tumor cells. Patients
with STAT6-expressing tumors had a
significantly better recurrence-free survival
when they had been treated with cisplatin
in combination with radiotherapy.
Notably, this effect was not seen in the
patients that had been treated with
radiotherapy alone. In fact, there was a
clear trend for a lower recurrence-free
survival in this treatment group for
patients with STAT6-expressing tumors.
These findings, which are in accordance
with previous studies in colon cancer,
8
indicate that tumor STAT6 expression in
itself results in a poor prognosis due to
its immune-evasive potential. However,
because platinum compounds inactivate
this negative pathway, tumor STAT6
expression results in a better prognosis
when treated with this group of drugs.
Whether STAT6 inactivation has only
immunologic consequences still remains
an unanswered question, since other
studies suggest a role for STAT6 in
enhancing tumor cell proliferation and
invasion.
9 More studies on the effects of
platinum-induced STAT6 inactivation on
tumor cell biology are therefore warranted.
In addition, to truly assess the prognostic
and predictive value of STAT6-expression
in platinum-sensitive tumors, prospective
clinical studies are needed.
Combining the recent data, a picture
emerges wherein platinum chemothera-
peutics transform the immunosuppressive
tumor microenvironment into an immu-
nostimulatory site. A number of steps can
be distinguished in this process (1) induc-
tion of immunogenic cell death which
leads to the release of tumor antigens and
results in DC activation,
1 (2) enhancing
the T cell stimulatory capacity of DCs
through downregulation of PD-L1 and 2
4
and (3) sensitization of tumor cells for T cell
mediated killing by expression of mannose-6
receptor and downregulation of PD-L2.
3,4
In conclusion, from these studies it is
evident that platinum chemotherapeutics
not only have a direct cytotoxic effect but
also have significant immune modulating
effects. Since the effector cells of the
immune system appear to be unaffected
as demonstrated in patients receiving
oxaliplatin or cisplatin,
10 it is tempting to
speculate that the anti-tumor efficacy
could be further increased if the immuno-
logical effect of platinum drugs could
be exploited and augmented by combin-
ing it with other immunotherapeutic
approaches. Since several novel immu-
notherapies have been recently approved
2
these findings could be readily translated
to the clinic.
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Figure1. Immune modulation by platinum chemotherapeutics. (A) Immunosuppressive tumor microenvironment. IL-4/IL-13 production by tumor cells
and immune cells (not shown) leads to STAT6 phosphorylation in DCs and tumor cells. STAT6 phosphoylation leads to upregulation of PD-L2 expression
resulting in immune evasion by induction of T cell tolerance and anergy. (B) Platinum treated tumor microenvironment. Platinum chemotherapeutics
have a direct cytotoxic effect and inhibit STAT6 phosphorylation leading to a downregulation of PD-L2 expression. Decreased PD-L2 expression leads to
increased activation and proliferation of T cells by DCs and enhanced recognition of tumor cells by T cells.
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